Avalo Therapeutics Inc SEC Filings

Form 4 overview: Avalo Therapeutics, Inc. (AVTX) filed a Form 4 disclosing an equity-based compensation grant to board member Samantha Truex on 06/17/2025. The filing reports no sales or disposals of common stock; it solely records the award of new derivative securities.

Key terms of the option grant

• Security: Stock Option (Right to Buy) on AVTX common shares
• Underlying shares: 20,100
• Exercise price: $4.47 per share
• Vesting schedule: 100 % cliff vest on the first anniversary of the grant date, conditional on Ms. Truex’s continued board service
• Expiration: 06/17/2035 (10-year term)
• Ownership form after transaction: Direct

The transaction increases Ms. Truex’s derivative beneficial ownership to 20,100 options. No non-derivative (common stock) positions are listed in this filing, and there is no indication of Rule 10b5-1 trading plan use.

Investor takeaway: The filing reflects routine board compensation rather than market activity. While the additional options further align the director’s incentives with shareholders, the relatively small size (≈20 k shares) suggests limited immediate impact on AVTX’s share float or insider-sentiment signals.

Form 4 filing overview: On 18 June 2025, Avalo Therapeutics, Inc. (AVTX) reported that director Mitchell Chan received a new equity award on 17 June 2025. The grant consists of 20,100 non-qualified stock options with an exercise price of $4.47 per share, expiring 17 June 2035. The option vests 100 % on the first anniversary of the grant date, provided the director remains in service at that time.

Post-transaction holdings: Following the grant, Chan directly beneficially owns 20,100 derivative securities (options). No acquisitions or dispositions of common shares were reported in Table I, so the filing only affects derivative ownership.

Implications for investors: The award is a routine component of board compensation that aligns the director’s incentives with shareholder interests by linking future gains to share price appreciation above $4.47. Although the 20,100-share underlying amount represents minimal potential dilution relative to Avalo’s outstanding share count, it does marginally increase fully-diluted share capital. No cash outflow or immediate EPS impact occurs because the options are non-cash grants and forfeiture is possible if service ceases before vesting.

Materiality assessment: The transaction is not a signal of insider buying or selling; rather, it is a standard equity grant with no direct indication of management’s near-term outlook. Consequently, its market impact should be limited, but it demonstrates continued board engagement and retention efforts.

Avalo Therapeutics director Jonathan Goldman received a new stock option grant on June 17, 2025. The derivative security details include:

• Granted 20,100 stock options to purchase common stock
• Exercise price set at $4.47 per share
• Options will vest 100% on June 17, 2026 (first anniversary of grant date)
• Expiration date is June 17, 2035
• Vesting is contingent on continued service as director

The Form 4 filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity ownership potential.

Insider Trading Alert: Avalo Therapeutics (AVTX) director Gilla Kaplan received a stock option grant on June 17, 2025. The derivative securities transaction involved 20,100 stock options with the following key terms:

• Exercise price set at $4.47 per share
• Options expire on June 17, 2035
• 100% vesting occurs on the first anniversary of grant date
• Vesting conditional on continued service as director

This Form 4 filing discloses a standard director compensation stock option grant, suggesting continued alignment of director interests with shareholders through equity-based compensation. The filing was signed by Donald R. Reynolds via Power of Attorney on June 18, 2025.

Avalo Therapeutics director Aaron Kantoff received a new stock option grant on June 17, 2025. The derivative security details include:

• Granted 20,100 stock options to purchase common stock
• Exercise price set at $4.47 per share
• Options will vest 100% on June 17, 2026 (first anniversary of grant date)
• Expiration date is June 17, 2035
• Vesting is contingent on continued service as director

This Form 4 filing was submitted by Donald R. Reynolds via power of attorney on June 18, 2025. The grant appears to be part of the company's director compensation program. The options represent a direct ownership interest and will become exercisable upon vesting.

Insider Trading Alert: Michael Thomas Heffernan, Director of Avalo Therapeutics (AVTX), was granted stock options on June 17, 2025. The transaction details include:

• Received 29,500 stock options to purchase common stock
• Exercise price set at $4.47 per share
• Options will vest 100% on June 17, 2026 (first anniversary of grant date)
• Options expire on June 17, 2035
• Vesting is contingent on continued service as Director

This Form 4 filing represents a standard director compensation grant and was reported within the required two-business-day filing window. The transaction was executed directly (not through indirect ownership) and was documented via power of attorney by Donald R. Reynolds.

Director Rita Jain of Avalo Therapeutics (AVTX) received a stock option grant on June 17, 2025, according to a Form 4 filing. The key details include:

• Granted 40,200 stock options to purchase common stock at an exercise price of $4.47 per share
• Options will vest in three equal installments on the first, second, and third anniversary of the grant date
• Options expire on June 17, 2035
• Vesting is contingent on continued service as director

This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This transaction represents a new position for the director, as no prior holdings were reported.